Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASTOP2: Second TKI Discontinuation in CML After Prior Failed Stop
2024-515409-25-00Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myelogenous leukemia (CML), sponsored by Region Uppsala. Planned start Sep 2024; status: authorised.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-515409-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515409-25-00.